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OBJECTIVE: To quantify the effect of treatment dura-
tion on life-long societal net value of glaucoma treatment
according to its treatment line in three European coun-
tries. METHODS: A Markov model was used to repro-
duce the average discounted (5%) cost and outcome of
glaucoma treatment over 30 years. Clinical states were
ﬁrst to fourth line treatment, no treatment, laser, surgery,
blindness and death. All patients started ﬁrst line, went
successively to the next line after failure. After each
failure (and always after the fourth line) patients could
have either laser or surgery followed by no treatment, or
a new ﬁrst line treatment. Transition probabilities and
resource utilisation (RU) came from of a cross-sectional
study with 5 years retrospective data collection for 
the glaucoma treatment, and from national statistics in
France. Expert interviews were conducted in Germany
and the Netherlands to collect RU. In-patient and outpa-
tient direct medical costs and indirect costs were esti-
mated from a societal point of view. Sensitivity analyses
and second order Monte-Carlo simulation were per-
formed. RESULTS: Life expectancy of this cohort (57
years old on average, 52% females) was 23.2 years.
Patients spent 9.8 years in ﬁrst line, 4.2 in second, 3.0 in
third, 2.2 in fourth, 3.6 without treatment, had 0.35
lasers and 1.17 surgeries. These ﬁgures became, respec-
tively, 11.77, 3.36, 2.41, 1.86, 3.47, 0.36 and 1.054 if
ﬁrst line treatment duration increased by 30% and 9.35,
5.52, 2.55, 1.97, 3.46, 0.35, 1.079 for a 30% 2nd line
duration increased. In France, €430 and €108 were saved
for a 30% ﬁrst and second line increased, respectively.
These ﬁgures were €241 and €30 in Germany and €257
and €55 in the Netherlands. Patients spent less time in
long-term institution. CONCLUSION: Increasing ﬁrst
line or second line glaucoma treatment duration is a cost
saving approach over life of a patient according to our
model.
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OBJECTIVE: To compare model estimates of the cost-
effectiveness of latanoprost and travoprost versus timolol.
METHODS: The probability of developing a visual ﬁeld
defect (VFD) was estimated using data from a double-
masked double-dummy Phase III multi-centre clinical trial
comparing travoprost 0.004%od, latanoprost 0.005%
od and timolol 0.5%bid, and the 2 discriminant func-
tions published by Stewart (1993). A Markov model was
constructed to estimate the cost and effectiveness (time to
disease progression) of patients treated over ﬁve years for
two states: those who do and those who do not develop
a VFD. Resource utilisation was estimated from a 5-year
retrospective patient chart analysis in France, from the
UK General Practitioner Data Base in the UK, and from
expert interviews in Germany. Both costs and outcomes
were discounted at a 5% rate. The economic perspective
was that of the Heath Care Sick Fund. RESULTS: The
average time to disease progression was estimated to be
2.81 years with timolol, 3.28 with latanoprost and 3.42
with travoprost. In France, over 5 years, a latanoprost
treated-patient is predicted to cost 277.6 more than a
timolol-treated patient while the ﬁgure for a travoprost-
treated patient is EUR 403.7. In Germany, these ﬁgures
were €858.60 and €714.80, for latanoprost and travo-
prost respectively. The corresponding amounts in the UK
were €288.9 and €251.1. In the UK and in Germany,
travoprost was predicted to be more effective and less
costly than latanoprost. Comparing the prostaglandin
analogues in France, travoprost’s incremental additional
5 year cost is modelled to be €951.4 per additional disease
free year. CONCLUSION: According to our model,
travoprost is a cost-effective alternative to timolol and
latanoprost.
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OBJECTIVE: The aim of this study was to compare the
cost-effectiveness of intraocular lens material (PMMA,
silicone, acrylic hydrophilic, and hydrophobic) implanted
during cataract surgery with reference to Yag-laser cap-
sulotomy and Yag-laser complications in four European
countries (France, Italy, Germany and Spain). Setting: A
retrospective review of 1525 patients (eyes), aged 50 to
80 years, operated with phaco-emulsiﬁcation for cataract
in 1996 or 1997 in 16 surgical centres (4 per country).
METHODS: The study was conducted using a cost-
effectiveness approach. Medical charts were reviewed to
collect retrospective information during the 3-year period
following cataract surgery in order to identify patients
who underwent YAG laser capsulotomy post-operatively.
Clinical data were combined with unit costs assessed by
experts for Yag laser capsulotomy and Yag complications.
A cost-effectiveness ratio (cost per patient without Yag
laser capsultomy intervention) was estimated in relation
